Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
CJC-1295 / Ipamorelin
Batch #
N/A
Formula
C38H49N9O5
Mol Wt
711.9 g/mol
CAS
170851-70-4
latest
ISO 17025
8× Testing
99.63%
Purity
VariantCJC-1295 / Ipamorelin
COA ##13140
Labeled5mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.63%
✓
Net Peptide Content - 5mg
✓
Identity (HPLC) - Ipamorelin
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
02
Ipamorelin, the first selective growth hormone secretagogue
03
Growth hormone secretagogues: history, mechanism of action, and clinical development
04
CJC-1295, a long-acting growth hormone releasing factor analog
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
